Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.

Ann Transl Med · 2021 · PMC7859789 · PMID 33553327

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

marginally significantP=0.060so close (0.05 < p ≤ 0.1)

Younger patients (age <65) could get marginally significant OS benefit rather than PFS benefit from ICIs (univariate: HR 1.526, P=0.060; multivariate: HR 1.593, P=0.050).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.